Team

Manijeh Goldberg, PH.D., M.B.A., M.S.

CHIEF EXECUTIVE OFFICER

Manijeh is the Founder and CEO of Privo. She has over 20 years of experience in the biomedical industry, in large companies and five startups (one was acquired for $275M).  She has developed US Key Opinion Leader (KOL) relationships, successfully lobbied to get PRV111 into a large, NIH funded clinical study, planned and executed training and helped drive on-time trial enrollment. Additionally, Manijeh is driving the execution of a second generation Privo’s products. Her current focus is to conduct clinical trials, get PRV111’s second-generation products through the FDA and explore initiating a second US clinical trial. Additional responsibilities include business development, general management and driving the overall success of Privo’s research and products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, and an MS in Computer Science and Mathematics.


Daniel Geffken

INTERIM CHIEF FINANCIAL OFFICER

Daniel Geffken is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. As Co-founder and Managing Director of Danforth Advisors, he leads a team of more than 90 consultants in strategic CFO advisory, accounting and operational support for over 100 clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, Cidara Therapeutics, Editas Medicine, Homology Medicines, Promedior, ProMIS Neurosciences and Stealth BioTherapeutics.

Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. Among his pre-Danforth roles, he served as CFO of Transkaryotic Therapies, where he negotiated and closed five equity transactions totaling $600 million – including the largest private placement in biotechnology history at the time. Daniel has been a board member and chairman of audit and compensation committees of both public and private life science companies, including Windtree Therapeutics. He holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School.


Edward Garmey, MD

Interim CMO

A former academic hematologist-oncologist at Memorial Sloan-Kettering Cancer Center, Edward has served as CMO for leading private and public biopharmaceutical companies during his 15 years in the industry. Prior to a transition into consulting in 2015, Dr. Garmey served as Chief Medical Officer and Senior Vice President at Cerulean Pharma where he oversaw the initiation of multi-national clinical trials for multiple drug programs and helped lead the company’s successful $67 MM IPO. Dr. Garmey is an alumnus of Harvard and New York Universities and completed his medical training at New York’s Mount Sinai Medical Center, the Children’s Hospital of Los Angeles, and Sloan-Kettering.


Sam Goldberger, MD, MBA

SR. CLINICAL MONITOR

Sam is a well-known reconstructive and plastic surgeon with significant experience in the removal of squamous cell carcinoma and other epithelium tumors. Sam received his medical doctorate degree from the Albert Einstein College of Medicine in New York. He holds an MBA from MIT Sloan School of Management and a BS from MIT’s School of Biology.  Sam has been practicing as a reconstructive surgeon since 1991 and has performed thousands of surgical procedures. In addition to his expertise in medicine, Sam is well-experienced in innovation, entrepreneurship, and growing successful business.


Bruce Sunstein, JD

INTELLECTUAL PROPERTY

Bruce is a patent and IP strategist for market leaders and innovators in diverse industries including pharmaceuticals, biotechnology, bioinformatics, and medical devices. He is also an experienced expert witness, an arbitrator, in intellectual property disputes. Bruce was selected by his peers for inclusion in the Best Lawyers in America in the fields of Patent Law and Intellectual Property-Litigation. Bruce is the founder of Sunstein LLP in Boston.


Joanna Ward

GMP MANUFACTURING

Over 30 years of experience in CMC strategy and manufacturing oversight across all development phases of biological and pharmaceutical products, ranging from pre-IND to commercial approvals of novel oncology therapies. Joanna holds a BSc in Plant biology from the University of Hull in the UK.

Expert in authoring CMC sections of IND, IMPD, PMDA, CFDA and BLA’s. Responsible for development of complex commercial and clinical supply chains with global logistics, including complex contract negotiations and execution.


Jeff Fellows

CMC

Jeff is a seasoned pharmaceutical industry professional with over 30 years of drug development experience leading regulatory development efforts ranging from pre-IND to post-approval. Experienced in strategic development across numerous product platforms and therapeutic areas covering both North America and Europe with extensive clinical trial application filings and health authority interactions. He has a B.S. in Microbiology from Oregon State University.


Scientific Advisors

John Ripple

John Ripple founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development, and capital fundraising activities.
He previously served as CEO of 5 venture-backed biotech companies, including Exonics Therapeutics (acquired by Vertex), Virdante Pharmaceuticals (acquired by Momenta), and Syntonix Pharmaceuticals (acquired by Biogen).

Mr. Ripple also held positions in business development, entrepreneur-in-residence, medical device marketing, and management consulting.  He started his career as an aerospace engineer at NASA.  He currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), on the Board of Directors and Treasurer of the Children’s Melanoma Prevention Foundation, and as an advisor to the MIT Deshpande Center for Technological Innovation.

Mr. Ripple received a BS in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.


Nishant Agrawal, M.D.

Dr. Nishant Agrawal, is the director of Head and Neck Surgical Oncology at the University of Chicago Medicine. Dr. Agrawal specializes in the management of patients with benign and malignant tumors of the head and neck. His work has achieved international recognition in the field of head and neck surgical oncology, and head and neck cancer genetics. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University.


James Demetroulakos, M.D.

Dr. Demetroulakos is Chief of Otolaryngology/ Head and Neck Surgery at the North Shore Medical Center and Attending Staff at Mass General Hospital and Mass Eye and Ear Infirmary. He is an emeritus staff at Harvard Medical school and the Uniformed Services School of the Health Sciences.  James received his medical and undergraduate degrees from Brown University through their seven-year med program.


Bharat Yarlagadda M.D.

Dr. Bharat Yarlagadda is the director of the Head and Neck Cancer Center of the Lahey Cancer Institute in Burlington, MA. His clinical practice specializes in the care of patients with benign and malignant tumors of the head and neck, including robotic surgery of the head and neck and microvascular reconstruction. He serves on numerous quality and safety committees at Lahey Hospital and Medical Center, as well as an elected member of the Medical Executive Committee. He is an assistant professor of Otolaryngology-Head and Neck Surgery at Boston University School of Medicine, with a research focus on quality outcomes and surgical simulation.


Board Members

Manijeh Goldberg, PH.D., M.B.A., M.S.

CHAIRMAN OF THE BOARD

Manijeh is the Founder and CEO of Privo. She has over 20 years of experience in the biomedical industry, in large companies and five startups (one was acquired for $275M).  She has developed US Key Opinion Leader (KOL) relationships, successfully lobbied to get PRV111 into a large, NIH funded clinical study, planned and executed training and helped drive on-time trial enrollment. Additionally, Manijeh is driving the execution of a second generation Privo’s products. Her current focus is to conduct clinical trials, get PRV111’s second-generation products through the FDA and explore initiating a second US clinical trial. Additional responsibilities include business development, general management and driving the overall success of Privo’s research and products. Manijeh holds a Ph.D. in Biomedical Engineering, an MS in Health Sciences and Technology from Harvard Medical School, an MBA from MIT Sloan School of Management, and an MS in Computer Science and Mathematics.


Jane Hirsh

Ms. Hirsh was Founder, President, and CEO of Copley Pharmaceutical, Inc., a large, successful generic pharmaceutical company. During her tenure, the Company completed over 80 ANDAs and attained revenues of $160 million prior to its acquisition. In 1993, Hoechst Celanese Corporation, the chemical and drug concern, acquired 51 percent of Copley Pharmaceutical Inc. for $546 million. In 2000, Copley was sold to Teva Pharmaceuticals. Jane is a co-inventor on over 9 patent applications and has over 40 years of experience in the pharmaceutical and related healthcare industries. In 2003, Ms. Hirsh co-founded and served as Chairman of Collegium Pharmaceutical. As a specialty pharmaceutical company, Collegium focused on intellectual property development under jane’s leadership. Onset Therapeutics, a dermatological specialty company, was founded in 2007 as a subsidiary of Collegium and sold to Precision Dermatology in 2010. In addition, Jane has served on the Board of Trustees for Tufts University and the Museum of Science, Boston.  


James Mackay, PH.D

Dr. Mackay is the founder, president, and CEO of Aristea Therapeutics, an immunology company focused on developing treatments for orphan diseases. Prior to founding Aristea Therapeutics, Dr. Mackay led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He was President & CEO of Ardea Biosciences from 2013 to 2018. He set up an innovative model for Ardea that retained the biotech’s independence and accountability for the development of the gout franchise while developing a collaborative relationship with the parent company, AstraZeneca. Prior to Ardea Biosciences, Dr. Mackay was Global Product Vice President for Diabetes franchise at AstraZeneca where he played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. He held a number of senior roles in AstraZeneca’s Clinical Development Function including portfolio management of all AstraZeneca Clinical resources and budget worldwide and management of AstraZeneca’s strategic partnerships with drug development CROs.


Contact Us
close slider

Contact Us